DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell...

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Trabectedin is a second-line therapy for soft-tissue sarcoma with moderate efficacy.
• Recombinant methioninase (rMETase) is an enzyme with potential therapeutic applications.

Purpose of the Study:

• To evaluate the synergistic efficacy of rMETase combined with trabectedin on fibrosarcoma cells in vitro.
• To compare the combination's effect on fibrosarcoma cells versus normal fibroblasts.

Main Methods:

• HT1080 human fibrosarcoma cells and Hs27 normal human fibroblasts were used.
• Cells were divided into four treatment groups: control, trabectedin alone, rMETase alone, and combination therapy.
• Dual-color cells were utilized to quantify nuclear fragmentation.

Main Results:

• The combination of rMETase and trabectedin demonstrated high synergy in decreasing fibrosarcoma cell viability.
• No synergistic effect was observed on normal fibroblasts, indicating selective toxicity.
• Synergistic nuclear fragmentation was observed in fibrosarcoma cells treated with the combination.

Conclusions:

• The combination of trabectedin and rMETase is highly synergistic against fibrosarcoma cells in vitro.
• This combination therapy holds promise for improving outcomes in soft-tissue sarcoma patients.
• The lack of synergy in normal fibroblasts suggests a favorable safety profile for the combination.